Nurdati (prolgolimab/nurulimab) / Biocad 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nurdati (prolgolimab/nurulimab) / Biocad
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Recruiting
3
270
RoW
BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo
Biocad
Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
04/24
04/25
NEO-MIMAJOR, NCT05751928: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Recruiting
3
410
RoW
BCD-217, nurulimab+prolgolimab, anti-PD1, Excision of the primary lesion, Regional lymphadenectomy
Biocad
Melanoma Stage III, Melanoma (Skin)
01/27
06/27
OBERTON, NCT03913923: Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

Active, not recruiting
2
117
RoW
BCD-217, BCD-100, Placebo
Biocad
Melanoma, Melanoma Metastatic
07/23
12/23

Download Options